Medtronic plc (MDT) Cash Flow Statement
Medtronic plc (MDT) generated $8.0B of operating cash flow over the twelve months to 2026-07-31, spent $1.9B on capital expenditure and had free cash flow of $6.1B, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-07-31 · read by EquiReason
MDTMedtronic plcFollow MDT — free
—
Price chart with a free account
- Market cap
- 122.0B
- P/E TTM
- 23.4
- Dividend yield
- 3.0%
- 52-week
- —
- Next earnings
- 16 Nov, in 22 days
| Line | FY2015 Apr 15 | FY2016 Apr 16 | FY2017 Apr 17 | FY2018 Apr 18 | FY2019 Apr 19 | FY2020 Apr 20 | FY2021 Apr 21 | FY2022 Apr 22 | FY2023 Apr 23 | FY2024 Apr 24 | FY2025 Apr 25 | FY2026 Apr 26 | TTM Jul 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 4.90 | 5.22 | 6.88 | 4.68 | 7.01 | 7.23 | 6.24 | 7.35 | 6.04 | 6.79 | 7.04 | 7.33 | 8.04 | |
| Capital expenditure | 0.57 | 1.05 | 1.25 | 1.07 | 1.13 | 1.21 | 1.36 | 1.37 | 1.46 | 1.59 | 1.86 | 1.90 | -1.90 | |
| Free cash flow | 4.33 | 4.17 | 5.63 | 3.62 | 5.87 | 6.02 | 4.89 | 5.98 | 4.58 | 5.20 | 5.19 | 5.43 | 6.13 | |
| Dividends paid | 1.34 | 2.14 | 2.38 | 2.49 | 2.69 | 2.89 | 3.12 | 3.38 | 3.62 | 3.67 | 3.59 | 3.64 | — | |
| Share repurchases | 1.92 | 2.83 | 3.54 | 2.17 | 2.88 | 1.33 | 0.65 | 2.54 | 0.65 | 2.14 | 3.24 | 1.04 | — | |
| Stock-based compensation | 0.44 | 0.38 | 0.35 | 0.34 | 0.29 | 0.30 | 0.34 | 0.36 | 0.36 | 0.39 | 0.43 | 0.46 | — |
USD billions · SEC XBRL
Medtronic plc — questions
- What is Medtronic plc's operating cash flow?
- $8.0B over the twelve months to 2026-07-31.
- How much does Medtronic plc spend on capital expenditure?
- $1.9B over the twelve months to 2026-07-31.
- What is Medtronic plc's free cash flow?
- $6.1B over the twelve months to 2026-07-31: operating cash flow minus capital expenditure.
Every figure on this page comes from Medtronic plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.